Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Methylnaltrexone bromide RELISTOR

Methylnaltrexone was launched in 2008 for the treatment of OIC in patients with advanced illness receiving palliative care, when response to laxative therapy has not been sufficient. Due to its poor oral bioavailability, 4 is administered subcutaneously every other day. Approximately 50% of the drug is excreted in the urine and feces with 85% eliminated unchanged [30]. [Pg.148]

Oral 400, 800 mg/5 mL aqueous suspension Methylnaltrexone bromide (Relistor)... [Pg.1336]

See other pages where Methylnaltrexone bromide RELISTOR is mentioned: [Pg.148] [Pg.704] [Pg.148] [Pg.704]

See also in sourсe #XX -- [ Pg.144 , Pg.148 , Pg.153 ]

SEARCH

Methylnaltrexone

Methylnaltrexone bromide

Relistor